Access to Biomarker Testing

Share

Biomarker testing is key to unlocking precision medicine.

Biomarkers are often used to help determine the best treatment for a patient, but not all communities are benefitting from the latest advancements in biomarker testing and precision medicine.


Progress in improving cancer outcomes increasingly involves the use of precision medicine. Biomarker testing is an important step for accessing precision medicine including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. But without action to expand coverage of and access to biomarker testing, advances in precision medicine could increase existing disparities in cancer outcomes by race, ethnicity, income, and geography.

ACS CAN is working to expand insurance coverage of comprehensive biomarker testing. 

Map of biomarker testing coverage legislation

Legislation introduced: CA, MN, NY, OH, WA
Legislation passed: AZ, IL, LA, RI

Get more information about our campaigns.

California | New York | Texas

Biomarker testing helps ensure cancer patients get the right treatment at the right time.

It allows doctors to precisely target a specific cancer so patients may not have to undergo more generalized treatments like chemo and radiation that may not work as well for them.

Patient and Provider Stories

Heather

Heather’s Story

Pete

Pete’s Story

Ruth

Ruth’s Story

Carla

Carla’s Story

 

Take Action

Researcher

Help cancer patients get the right treatment at the right time!

Biomarker testing is the latest advanced in cancer research that is personal to the patient and their cancer, helping ensure patients get the right treatment at the right time. 

Latest Updates

June 21, 2022
California

The California Assembly Health Committee passed a bill today that would ensure comprehensive biomarker testing is covered by more insurance plans, including Medi-Cal, when supported by medical and scientific evidence.

May 19, 2022
Rhode Island

Today, the Rhode Island Senate passed legislation that would ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it.

May 6, 2022
Texas

WICHITA FALLS, TX – May 6, 2022 – Family and friends recall former Wichita Falls resident Jackie Bush as the definition of bravery, strength and a force to be reckoned with. She undoubtedly left her mark in Texas, and on the hearts of fellow volunteers and legislatures as a lead

April 21, 2022
California

The California Senate Health Committee voted to advance a bill that would increase access to biomarker testing, a critical step in accessing precision medicine treatments that can lead to fewer side effects, improved survival, better quality of life and potentially lower costs for cancer patients.

Access to Biomarker Testing Resources

Precision medicine in cancer involves targeted therapies which work by interfering with specific cellular processes involved in the growth, spread, and progression of cancer. Treatment with targeted therapy often requires diagnostic testing to identify specific cancer biomarkers. Testing patients for biomarkers is integral to precision medicine in cancer care.

Advances in precision medicine have led to targeted cancer therapies that have improved patient outcomes and quality of life within populations of cancer patients with very specific biomarkers. Testing patients for cancer biomarkers is integral to identify those who may benefit from targeted therapy. Despite the importance of such testing, many cancer patients are not tested for biomarkers. This fact sheet highlights recent advancements in targeted cancer therapies and data from ACS CAN Survivor Views surveys of cancer patients and survivors assessing barriers to biomarker testing.